{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:03Z","timestamp":1794047463130,"version":"4.8.0"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC rituximab maintenance in patients with extranodal marginal zone lymphoma (MZL) who received front-line treatment with chlorambucil plus rituximab. Study treatment was an induction phase with oral chlorambucil 6 mg\/m2\/day on weeks 1-6, 9-10, 13-14, 17-18, and 21-22, and intravenous rituximab 375 mg\/m2 on day 1 of weeks 1-4, and 1,400 mg SC on weeks 9, 13, 17, and 21. Then, a maintenance phase followed with rituximab administered at 1,400 mg SC every two months for two years. Of the 112 patients enrolled, 109 were evaluated for efficacy. The CR rates increased from 52% at the end of the induction phase to 70% upon completion of the maintenance phase. With a median follow-up of 5.8 years, the 5-year event-free, progression-free, and overall survival rates were 87% (95% CI: 78-92), 84% (95% CI: 75-89), and 93% (95% CI: 86-96), respectively. The most common grade \u22653 toxicities were neutropenia (33%) and lymphocytopenia (16%). Six patients experienced treatment-related serious adverse events, including fever of unknown origin, sepsis, pneumonia, respiratory failure, severe cerebellar ataxia, and fatal acute myeloid leukemia. The trial showed that SC rituximab did not improve the CR rate at the conclusion of the induction phase, which was the main endpoint. Nevertheless, SC rituximab maintenance might have facilitated long-term disease control, potentially contributing to enhanced event-free and progression-free survival.<\/jats:p>","DOI":"10.3324\/haematol.2023.283918","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:34:59Z","timestamp":1708576499000},"page":"2564-2573","source":"Crossref","is-referenced-by-count":2,"title":["IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma"],"prefix":"10.3324","volume":"109","author":[{"given":"Anastasios","family":"Stathis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Pirosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Orsucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Gaia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Gui\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Conconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Cabras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Capochiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaldo","family":"Occhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Devizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pietrantuono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Ielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Borgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"64541","doi-asserted-by":"crossref","unstructured":"Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med. 2022; 386(6):568-581.","DOI":"10.1056\/NEJMra2102568"},{"key":"64542","doi-asserted-by":"crossref","unstructured":"Cerhan JR, Habermann TM. Epidemiology of marginal zone lymphoma. Ann Lymphoma. 2021; 5:1.","DOI":"10.21037\/aol-20-28"},{"key":"64543","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Cascione L, Conconi A. A MALT lymphoma prognostic index. Blood. 2017; 130(12):1409-1417.","DOI":"10.1182\/blood-2017-03-771915"},{"key":"64544","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Reis IM, Habermann TM. Revised MALT-IPI: a new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma. Am J Hematol. 2022; 97(12):1529-1537.","DOI":"10.1002\/ajh.26715"},{"key":"64545","doi-asserted-by":"crossref","unstructured":"Conconi A, Thieblemont C, Cascione L. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica. 2020; 105(11):2592-2597.","DOI":"10.3324\/haematol.2019.237990"},{"key":"64546","doi-asserted-by":"crossref","unstructured":"Luminari S, Merli M, Rattotti S. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019; 134(10):798-801.","DOI":"10.1182\/blood.2019001088"},{"key":"64547","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Zhao W, Desai A. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019; 94(5):585-596.","DOI":"10.1002\/ajh.25446"},{"key":"64548","doi-asserted-by":"crossref","unstructured":"Zucca E, Conconi A, Martinelli G. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017; 35(17):1905-1912.","DOI":"10.1200\/JCO.2016.70.6994"},{"key":"64549","doi-asserted-by":"crossref","unstructured":"Salar A, Domingo-Domenech E, Panizo C. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017; 130(15):1772-1774.","DOI":"10.1182\/blood-2017-07-795302"},{"key":"64550","doi-asserted-by":"crossref","unstructured":"Becnel MR, Nastoupil LJ, Samaniego F. Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019; 185(5):874-882.","DOI":"10.1111\/bjh.15843"},{"key":"64551","doi-asserted-by":"crossref","unstructured":"Zucca E, Arcaini L, Buske C. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(1):17-29.","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"64552","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"64553","unstructured":"NCI. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. 2010. Publisher Full Text|"},{"key":"64554","doi-asserted-by":"crossref","unstructured":"Copie-Bergman C, Gaulard P, Lavergne-Slove A. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut. 2003; 52(11):1656.","DOI":"10.1136\/gut.52.11.1656"},{"key":"64555","doi-asserted-by":"crossref","unstructured":"Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995; 72(2):511-518.","DOI":"10.1038\/bjc.1995.364"},{"key":"64556","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"64557","unstructured":"Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 1980."},{"key":"64558","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"64559","doi-asserted-by":"crossref","unstructured":"Taverna C, Martinelli G, Hitz F. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03. J Clin Oncol. 2016; 34(5):495-500.","DOI":"10.1200\/JCO.2015.61.3968"},{"key":"64560","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005; 23(6):1088-1095.","DOI":"10.1200\/JCO.2005.12.191"},{"key":"64561","doi-asserted-by":"crossref","unstructured":"Williams ME, Hong F, Gascoyne RD. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016; 173(6):867-875.","DOI":"10.1111\/bjh.14007"},{"key":"64562","doi-asserted-by":"crossref","unstructured":"Salles G, Seymour JF, Offner F. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42-51.","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"64563","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Koenigsmann M, Chow KU. Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2018; 36(15_suppl):7515.","DOI":"10.1200\/JCO.2018.36.15_suppl.7515"},{"key":"64564","doi-asserted-by":"crossref","unstructured":"Zelenetz AD, Gordon LI, Abramson JS. NCCN Guidelines\u00ae Insights: B-cell lymphomas, version 6.2023. J Natl Compr Canc Netw. 2023; 21(11):1118-1131.","DOI":"10.6004\/jnccn.2023.0057"},{"key":"64565","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Arcaini L, Watkins MP. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022; 6(7):2035-2044.","DOI":"10.1182\/bloodadvances.2021006844"},{"key":"64566","doi-asserted-by":"crossref","unstructured":"Oh SY, Kim WS, Kim JS. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Commun (Lond). 2019; 39(1):58.","DOI":"10.1186\/s40880-019-0403-7"},{"key":"64567","doi-asserted-by":"crossref","unstructured":"Herold M, Hoster E, Janssens A. Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial. Hemasphere. 2022; 6(3):e699.","DOI":"10.1097\/HS9.0000000000000699"},{"key":"64568","doi-asserted-by":"crossref","unstructured":"Buske C, Dreyling M, Alvarez-Larr\u00e1n A. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022; 7(2):100403.","DOI":"10.1016\/j.esmoop.2022.100403"},{"key":"64569","doi-asserted-by":"crossref","unstructured":"Au WY, Gascoyne RD, Le N. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol. 1999; 10(3):317-321.","DOI":"10.1023\/A:1008328226599"},{"key":"64570","doi-asserted-by":"crossref","unstructured":"Tajika M, Matsuo K, Ito H. Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT). J Gastroenterol. 2014; 49(5):843-852.","DOI":"10.1007\/s00535-013-0844-8"},{"key":"64571","doi-asserted-by":"crossref","unstructured":"Zucca E, Pinotti G, Roggero E. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. Ann Oncol. 1995; 6(7):726-728.","DOI":"10.1093\/oxfordjournals.annonc.a059292"},{"key":"64572","doi-asserted-by":"crossref","unstructured":"Shams\u2019ili S, Grefkens J, de Leeuw B. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003; 126(Pt 6):1409-1418.","DOI":"10.1093\/brain\/awg133"},{"key":"64573","doi-asserted-by":"crossref","unstructured":"Cao X, Xu CG. Paraneoplastic cerebellar degeneration: initial presentation of mucosa-associated lymphoid tissue lymphoma in a patient with primary Sj\u00f6gren\u2019s syndrome. Chin Med J (Engl). 2020; 133(8):1005-1007.","DOI":"10.1097\/CM9.0000000000000736"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283918\/76621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283918\/77348","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11459\/76621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:51Z","timestamp":1794045951000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283918","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}